Cellular markers in cystic fibrosis with a certain lung infection
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This study looks at special blood markers in people with cystic fibrosis who have or haven't been treated for a lung infection caused by nontuberculous mycobacteria. The goal is to better understand the body's response, which could lead to better treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have cystic fibrosis (any genetic type).
- You have already been part of the CIMeNT study.
- You are able to cough up sputum (phlegm) on your own or with help.
- You have not had a lung transplant.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for biological markers (substances in your body) that can show if a lung infection with Mycobacterium abscessus is getting worse. It may help researchers develop better ways to track and treat the infection in people with cystic fibrosis.
This trial follows people with cystic fibrosis to better understand how “nontuberculous mycobacteria” (a type of lung germ) spreads between healthcare visits and care settings. It may help improve future prevention and monitoring strategies for CF patients who have had these bacteria.
This study tests a new method to detect bacteria in the lungs of people with cystic fibrosis (CF) by analyzing mucus samples. It aims to improve how we diagnose and treat lung infections.
This study looks for simple signals (markers) that may show whether cystic fibrosis treatments are working. It includes people who take CF “modulator” medicines like ivacaftor, people who don’t, and people whose cystic fibrosis was ruled out after testing.
This study looks at how well CFTR-modulator medicines are working in people with cystic fibrosis, by checking specific “biomarkers” (measurable signals) in samples. Your care team may use the results to better understand how these medicines help, especially for certain CFTR changes.
This study looks at how lung infections and inflammation affect people with cystic fibrosis during severe flare-ups. It aims to understand which antibiotics work best and why, so your care team can choose the right treatment for you.
Hear when a new Non-Tuberculous Mycobacterial Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.